REPORT
Reality check: New drugs will cost more
The trend toward complex biologic drugs continues
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: July 2022
What's in the pipeline?
This Optum Rx Drug Pipeline Report issue highlights four drugs reflecting cutting-edge technologies and their expected approval times:
- Multiple myeloma
- Plaque psoriasis
- Two gene therapy drugs that target ultra-rare orphan conditions
Don't want to read the full report? Download the brief summary.
Related content
Report
Will these 4 new drugs re-shape the market?
Get the latest in this quarter’s Drug Pipeline Insights Report
Articles and blogs
Rush to judgement?
5 warning signs that faster FDA approvals may increase risks, costs
Articles and blogs
Will diabetes drugs help us tackle obesity?
Discover four things to know about new uses of GLP-1 drugs.